bpc-157 regulation fda status Approval Status: Is It Approved for Human Use? FDA removes BPC-157, KPV, Semax
Description
This store requires javascript to be enabled for some features to work correctly

Co-immunoprecipitation studies demonstrated that the peptide reduces eNOS/caveolin-1 binding by approximately 50%, effectively doubling the available eNOS for nitric oxide production

Jan 12;104(1):10717
Proposed Uses (Research Areas) Obesity and fat metabolism studies
